COA Patient Advocacy Network

CPAN begins the fourth quarter with a continued focus on its core mission: education.

You don’t want to miss the upcoming CPAN Advocacy Chat, we hope you can join us!

Enclosed is the 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.

Tedopi, a novel lung cancer vaccine, demonstrated improved survival and safety profile, according to preliminary findings from a phase 3 trial.

Recent developments in the use of immunotherapy for lung cancer have provided more treatment options for patients while potentially reducing side effect profiles.